Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study

Lupus Erythematosus ◽

Standard Of Care ◽

Japanese Patients ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Subgroup Analyses

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Case Medical Research ◽

10.31525/ct1-nct04058028 ◽

2019 ◽

Author(s):

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Faculty Opinions recommendation of Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8909956.9465054 ◽

2011 ◽

Author(s):

David Kluth ◽

Neeraj Dhaun

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Arthritis & Rheumatology ◽

10.1002/art.39856 ◽

2017 ◽

Vol 69 (2) ◽

pp. 362-375 ◽

Cited By ~ 78

Author(s):

Megan E. B. Clowse ◽

Daniel J. Wallace ◽

Richard A. Furie ◽

Michelle A. Petri ◽

Marilyn C. Pike ◽

...

Keyword(s):

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo

FRI0303 Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study

10.1136/annrheumdis-2018-eular.1734 ◽

2018 ◽

Author(s):

R. van Vollenhoven ◽

B.H. Hahn ◽

G.C. Tsokos ◽

C. Wagner ◽

P. Lipsky ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Phase 2 ◽

Efficacy And Safety ◽

S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study

10.1136/lupus-2018-abstract.45 ◽

2018 ◽

Cited By ~ 1

Author(s):

R van Vollenhoven ◽

B Hahn ◽

G Tsokos ◽

C Wagner ◽

P Lipsky ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Interleukin 12 ◽

Phase 2 ◽

Efficacy And Safety ◽

Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus

Arthritis & Rheumatology ◽

10.1002/art.41179 ◽

2020 ◽

Vol 72 (5) ◽

pp. 761-768 ◽

Cited By ~ 10

Author(s):

Ronald F. Vollenhoven ◽

Bevra H. Hahn ◽

George C. Tsokos ◽

Peter Lipsky ◽

Kaiyin Fei ◽

...

Keyword(s):

Phase Ii ◽

Lupus Erythematosus ◽

Crossover Trial ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

One Year

OP0041 MAINTENANCE OF EFFICACY AND SAFETY AND REDUCTION OF BILAG FLARES WITH USTEKINUMAB, AN INTERLEUKIN-12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 1-YEAR RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED, CROSSOVER STUDY

10.1136/annrheumdis-2019-eular.2449 ◽

2019 ◽

Author(s):

Ronald van Vollenhoven ◽

George Tsokos ◽

Robert Gordon ◽

Kim Hung Lo ◽

Y Irene Gregan ◽

...

Keyword(s):

Crossover Study ◽

Lupus Erythematosus ◽

Interleukin 12 ◽

Phase 2 ◽

Efficacy And Safety ◽

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Yearbook of Medicine ◽

10.1016/j.ymed.2011.09.006 ◽

2011 ◽

Vol 2011 ◽

pp. 18-19

Author(s):

R.S. Panush

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Case Medical Research ◽

10.31525/ct1-nct04294667 ◽

2020 ◽

Author(s):

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Study Participants

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-202760 ◽

2013 ◽

Vol 73 (1) ◽

pp. 183-190 ◽

Cited By ~ 161

Author(s):

Daniel J Wallace ◽

Kenneth Kalunian ◽

Michelle A Petri ◽

Vibeke Strand ◽

Frederic A Houssiau ◽

...

Keyword(s):

Multicentre Study ◽

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo